The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets
IntroductionChemokines are small, secreted peptides involved in the mediation of the immune cell recruitment. Chemokines have been implicated in several diseases including autoimmune diseases, viral infections and also played a critical role in the genesis and development of several malignant tumors...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2023.1154581/full |
| _version_ | 1827981666443853824 |
|---|---|
| author | Michela Roberto Giulia Arrivi Mattia Alberto Di Civita Giacomo Barchiesi Emanuela Pilozzi Paolo Marchetti Daniele Santini Federica Mazzuca Silverio Tomao |
| author_facet | Michela Roberto Giulia Arrivi Mattia Alberto Di Civita Giacomo Barchiesi Emanuela Pilozzi Paolo Marchetti Daniele Santini Federica Mazzuca Silverio Tomao |
| author_sort | Michela Roberto |
| collection | DOAJ |
| description | IntroductionChemokines are small, secreted peptides involved in the mediation of the immune cell recruitment. Chemokines have been implicated in several diseases including autoimmune diseases, viral infections and also played a critical role in the genesis and development of several malignant tumors. CXCL12 is a homeostatic CXC chemokine involved in the process of proliferation, and tumor spread. Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive tumors, that is still lacking effective therapies and with a dramatically poor prognosis.MethodWe conducted a scientific literature search on Pubmed and Google Scholar including retrospective, prospective studies and reviews focused on the current research elucidating the emerging role of CXCL12 and its receptors CXCR4 – CXCR7 in the pathogenesis of pancreatic cancer.ResultsConsidering the mechanism of immunomodulation of the CXCL12-CXCR4-CXCR7 axis, as well as the potential interaction with the microenvironment in the PDAC, several combined therapeutic approaches have been studied and developed, to overcome the “cold” immunological setting of PDAC, like combining CXCL12 axis inhibitors with anti PD-1/PDL1 drugs.ConclusionUnderstanding the role of this chemokine’s axis in disease initiation and progression may provide the basis for developing new potential biomarkers as well as therapeutic targets for related pancreatic cancers. |
| first_indexed | 2024-04-09T22:12:43Z |
| format | Article |
| id | doaj.art-53fb7425fe764cf6beee65526ab2cc88 |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-04-09T22:12:43Z |
| publishDate | 2023-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-53fb7425fe764cf6beee65526ab2cc882023-03-23T06:55:42ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2023-03-011310.3389/fonc.2023.11545811154581The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targetsMichela Roberto0Giulia Arrivi1Mattia Alberto Di Civita2Giacomo Barchiesi3Emanuela Pilozzi4Paolo Marchetti5Daniele Santini6Federica Mazzuca7Silverio Tomao8Oncology Unit (UOC) Oncologia A, Department of Radiological, Oncological and Anathomo-patological Science, Policlinico Umberto I, Sapienza University of Rome, Rome, ItalyOncology Unit, Department of Clinical and Molecular Medicine, Sant’ Andrea University Hospital, Sapienza University of Rome, Rome, ItalyOncology Unit (UOC) Oncologia A, Department of Radiological, Oncological and Anathomo-patological Science, Policlinico Umberto I, Sapienza University of Rome, Rome, ItalyOncology Unit (UOC) Oncologia A, Department of Radiological, Oncological and Anathomo-patological Science, Policlinico Umberto I, Sapienza University of Rome, Rome, ItalyDepartment of Clinical and Molecular Medicine, Anatomia Patologica Unit, Sant’ Andrea University Hospital, Sapienza University of Rome, Rome, ItalyScientific Direction, Istituto Dermopatico dell’Immacolata (IDI-IRCCS), Rome, ItalyOncology Unit (UOC) Oncologia A, Department of Radiological, Oncological and Anathomo-patological Science, Policlinico Umberto I, Sapienza University of Rome, Rome, ItalyOncology Unit, Department of Clinical and Molecular Medicine, Sant’ Andrea University Hospital, Sapienza University of Rome, Rome, ItalyOncology Unit (UOC) Oncologia A, Department of Radiological, Oncological and Anathomo-patological Science, Policlinico Umberto I, Sapienza University of Rome, Rome, ItalyIntroductionChemokines are small, secreted peptides involved in the mediation of the immune cell recruitment. Chemokines have been implicated in several diseases including autoimmune diseases, viral infections and also played a critical role in the genesis and development of several malignant tumors. CXCL12 is a homeostatic CXC chemokine involved in the process of proliferation, and tumor spread. Pancreatic ductal adenocarcinoma (PDAC) is one of the most aggressive tumors, that is still lacking effective therapies and with a dramatically poor prognosis.MethodWe conducted a scientific literature search on Pubmed and Google Scholar including retrospective, prospective studies and reviews focused on the current research elucidating the emerging role of CXCL12 and its receptors CXCR4 – CXCR7 in the pathogenesis of pancreatic cancer.ResultsConsidering the mechanism of immunomodulation of the CXCL12-CXCR4-CXCR7 axis, as well as the potential interaction with the microenvironment in the PDAC, several combined therapeutic approaches have been studied and developed, to overcome the “cold” immunological setting of PDAC, like combining CXCL12 axis inhibitors with anti PD-1/PDL1 drugs.ConclusionUnderstanding the role of this chemokine’s axis in disease initiation and progression may provide the basis for developing new potential biomarkers as well as therapeutic targets for related pancreatic cancers.https://www.frontiersin.org/articles/10.3389/fonc.2023.1154581/fullpancreatic ductal adenocarcinoma (PDAC)CXCL12CXCR4CXCR7chemokinesbiomarkers |
| spellingShingle | Michela Roberto Giulia Arrivi Mattia Alberto Di Civita Giacomo Barchiesi Emanuela Pilozzi Paolo Marchetti Daniele Santini Federica Mazzuca Silverio Tomao The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets Frontiers in Oncology pancreatic ductal adenocarcinoma (PDAC) CXCL12 CXCR4 CXCR7 chemokines biomarkers |
| title | The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets |
| title_full | The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets |
| title_fullStr | The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets |
| title_full_unstemmed | The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets |
| title_short | The role of CXCL12 axis in pancreatic cancer: New biomarkers and potential targets |
| title_sort | role of cxcl12 axis in pancreatic cancer new biomarkers and potential targets |
| topic | pancreatic ductal adenocarcinoma (PDAC) CXCL12 CXCR4 CXCR7 chemokines biomarkers |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2023.1154581/full |
| work_keys_str_mv | AT michelaroberto theroleofcxcl12axisinpancreaticcancernewbiomarkersandpotentialtargets AT giuliaarrivi theroleofcxcl12axisinpancreaticcancernewbiomarkersandpotentialtargets AT mattiaalbertodicivita theroleofcxcl12axisinpancreaticcancernewbiomarkersandpotentialtargets AT giacomobarchiesi theroleofcxcl12axisinpancreaticcancernewbiomarkersandpotentialtargets AT emanuelapilozzi theroleofcxcl12axisinpancreaticcancernewbiomarkersandpotentialtargets AT paolomarchetti theroleofcxcl12axisinpancreaticcancernewbiomarkersandpotentialtargets AT danielesantini theroleofcxcl12axisinpancreaticcancernewbiomarkersandpotentialtargets AT federicamazzuca theroleofcxcl12axisinpancreaticcancernewbiomarkersandpotentialtargets AT silveriotomao theroleofcxcl12axisinpancreaticcancernewbiomarkersandpotentialtargets AT michelaroberto roleofcxcl12axisinpancreaticcancernewbiomarkersandpotentialtargets AT giuliaarrivi roleofcxcl12axisinpancreaticcancernewbiomarkersandpotentialtargets AT mattiaalbertodicivita roleofcxcl12axisinpancreaticcancernewbiomarkersandpotentialtargets AT giacomobarchiesi roleofcxcl12axisinpancreaticcancernewbiomarkersandpotentialtargets AT emanuelapilozzi roleofcxcl12axisinpancreaticcancernewbiomarkersandpotentialtargets AT paolomarchetti roleofcxcl12axisinpancreaticcancernewbiomarkersandpotentialtargets AT danielesantini roleofcxcl12axisinpancreaticcancernewbiomarkersandpotentialtargets AT federicamazzuca roleofcxcl12axisinpancreaticcancernewbiomarkersandpotentialtargets AT silveriotomao roleofcxcl12axisinpancreaticcancernewbiomarkersandpotentialtargets |